Quintrio
Home

Stock overview

XTL Biopharmaceuticals Ltd. American Depositary Shares

XTLB

XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.54 – $1.68
Volume 2,681
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for XTLB.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for XTLB.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments

Beyond Air Inc. (NASDAQ:XAIR) has agreed to sell 85% of its subsidiary NeuroNOS Ltd. to XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) in exchange for 19.9% equity stake in XTL, $1 million cash, and up to $32.5 million in milestone-based payments. NeuroNOS, which focuses on autism therapeutics and holds FDA Orphan Drug Designations, will become XTL's flagship platform. Beyond Air shares surged 163.70% on the announcement.

Benzinga

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Biopharmaceuticals announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., positioning itself as a major player in autism therapeutics. The acquisition includes two Nobel Laureates in Chemistry and autism researcher Prof. Haitham Amal. NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma. XTL will pay 19.9% of its share capital, $1 million cash, and up to $32.5 million in milestone payments.

Investing.com

XTL Biopharmaceuticals Confirms Board and Auditor Appointments - Investing.com

XTL Biopharmaceuticals, an Israeli pharmaceutical company, announced the results of its Annual and Extraordinary General Meeting, including the re-election of board members and the appointment of independent auditors. The company also confirmed the acquisition of The Social Proxy Ltd., which will add two new directors to its board.

Benzinga

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos. Landos Biopharma shares jumped 171.2% to $21.70 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Next.e.GO N.V. (NASDAQ: EGOX) shares jumped 85.8% to $0.0730 after falling around 22% on Friday. Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines. MicroAlgo Inc. (NASDAQ: MLGO) climbed 34.3% to $5.40 after declining around 5% on Friday. XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) gained 32.4% to $3.4690. XTL Biopharmaceuticals recently entered into a binding term sheet to acquire all of the issued and outstanding share capital of Social Proxy. Nkarta, Inc. (NASDAQ: NKTX) gained 23.3% to $11.00 after the company priced $240 million underwritten offering. Target Hospitality Corp. (NASDAQ: TH) jumped 21.3% to $10.82 after the company received a buyout offer from TDR Capital. Swvl Holdings Corp. (NASDAQ: SWVL) rose 21.2% to $11.26. Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) surged 21% to $0.6949. Lucid Group, Inc. (NASDAQ: LCID) jumped 18.7% to $3.29 after the company announced a $1 billion investment by an affiliate of PIF. Sagimet Biosciences Inc. (NASDAQ: SGMT) rose 16.9% to $5.27 after the company reported FY results and announced the appointment of Tim Walbert and Paul Hoelscher to its Board of Director. Ocugen, Inc. (NASDAQ: OCGN) jumped 16.4% to $1.9101. The Third Circuit Court of Appeals recently upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen. Flora Growth Corp. (NASDAQ: FLGC) shares gained 15.2% to $1.8206 after surging around 34% on Friday. Forge Global Holdings, Inc. (NYSE: FRGE) shares gained 14.5% to $2.67 after ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 25, 20261-for-4reverse split
Feb 10, 20171-for-5reverse split